Taking advantage of the availability of biosimilars in Rheumatology
The Oxford AHSN’s Clinical Innovation Adoption programme is leading on a regional project which focusses on supporting regional partners to optimise the financial savings arising from the introduction of biosimilars in Rheumatology.
Working closely with the AHSN Medicines optimisation team and the AHSN Inflammatory Arthritis network over the last 6 months, the team has engaged a wide number of stakeholders in the region who will be impacted by the introduction of biosimilars.
From this engagement, the team recognised a number of opportunities to support commissioners, prover pharmacy and provider Rheumatology come to agreement on a position around the adoption of biosimilars.
The first biosimilar etanercept (Benepali) came to the UK market in Feb 2016 with a significant discount relative to pricing in the previous year. Partner organisations were faced with an opportunity to make savings through starting new patients on the biosimilar and/or switching existing etanercept patients from the originator compound to the biosimilar.
The project team have developed a number of shared resources for regional stake holders including template financial incentivisation (gain share) agreements; patient information and patient letters which have been used by partners with good feedback.